申请人:Rajasekaran Ayyappan K.
公开号:US10639304B2
公开(公告)日:2020-05-05
The disclosed molecules are inhibitors of Bcr-Abl and Src kinases. The molecules are cytotoxic to Gleevec resistant cells. Inhibitors of Bcr-Abl and Src kinases are used in the treatment of Chronic Myelogenous Leukemia among other diseases.
所公开的分子是 Bcr-Abl 和 Src 激酶的抑制剂。这些分子对格列卫耐药细胞具有细胞毒性。Bcr-Abl 和 Src 激酶抑制剂可用于治疗慢性骨髓性白血病等疾病。